Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Nault · SciRah

Researcher profile · Semantic Scholar

J. Nault

Share profile

J. Nault — researcher profile on SciRah

h-index: 59
Works: 327
Citations: 17K

Most-cited papers

Cholangiocarcinoma 2026: status quo, unmet needs and priorities
J. Banales, Pedro M. Rodrigues, S. Affò, J. B. Andersen +143 more
2025Nature reviews: Gastroenterology & hepatology93 citations Open access
Semantic Scholar
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
Qing-He Zeng, Christophe Klein, Stefano Caruso, P. Maille +41 more
2023The Lancet Oncology90 citations Open access
Semantic Scholar
Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments
C. Campani, S. Imbeaud, G. Couchy, M. Ziol +12 more
2024Gut58 citations
Semantic Scholar
Machine learning based radiomic models outperform clinical biomarkers in predicting outcomes after immunotherapy for hepatocellular carcinoma.
Mathew Vithayathil, Deniz Koku, C. Campani, J. Nault +4 more
2025Journal of Hepatology57 citations Open access
Semantic Scholar
EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma.
M. Marzioni, L. Maroni, Lars Aabakken, G. Carpino +7 more
2025Journal of Hepatology55 citations Open access
Semantic Scholar
Mapping the landscape of biliary tract cancer in Europe: challenges and controversies
L. Rimassa, Shahid A. Khan, B. Groot Koerkamp, S. Roessler +18 more
2025The Lancet Regional Health - Europe41 citations Open access
Semantic Scholar
Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab.
P. Sultanik, C. Campani, Edouard Larrey, Bertille Campion +8 more
2024Digestive and Liver Disease25 citations
Semantic Scholar
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab
C. Campani, A. Vallot, Haroun Ghannouchi, M. Allaire +11 more
2023Hepatology24 citations
Semantic Scholar
Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting
Manon Falette-Puisieux, J. Nault, Mohamed Bouattour, M. Lequoy +9 more
2023Therapeutic Advances in Medical Oncology22 citations Open access
Semantic Scholar
Rare primary liver cancers: An EASL position paper.
H. Wege, C. Campani, R. D. de Kleine, T. Meyer +7 more
2024Journal of Hepatology19 citations Open access
Semantic Scholar
Morphomolecular pathology and Genomic Insights into the Cells of Origin of Cholangiocarcinoma and combined Hepatocellular-Cholangiocarcinoma.
Rachel V. Guest, B. Goeppert, J. Nault, Daniela Sia
2024American Journal of Pathology16 citations Open access
Semantic Scholar
Integration of new technologies in the multidisciplinary approach to primary liver tumours: The next-generation tumour board.
J. Nault, Julien Caldéraro, M. Ronot
2024Journal of Hepatology16 citations Open access
Semantic Scholar
Tumor-based biomarkers and circulating tumor DNA for precision medicine in advanced hepatocellular carcinoma
S. Sidali, C. Campani, Jih-Yun An, J. Shim +1 more
2025Clinical and Molecular Hepatology14 citations Open access
Semantic Scholar
[18F]fluorodeoxyglucose and [18F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study.
J. Nault, M. Boubaya, Myriam Wartski, Anthony Dohan +35 more
2025The Lancet Gastroenterology and Hepatology13 citations Open access
Semantic Scholar
No correlation between MASLD and poor outcome of Atezolizumab‐Bevacizumab therapy in patients with advanced HCC
Francisca-Dora Copil, C. Campani, M. Lequoy, P. Sultanik +8 more
2024Liver international (Print)13 citations Open access
Semantic Scholar
Neutralization of acyl coenzyme A binding protein for the experimental prevention and treatment of hepatocellular carcinoma
Sijin Li, Omar Motiño, Flavia Lambertucci, Jonathan G. Pol +33 more
2025Cell Reports Medicine11 citations Open access
Semantic Scholar
Heterogeneity in adverse events related to atezolizumab-bevacizumab for hepatocellular carcinoma reported in real-world studies
C. Campani, Dimitrios Pallas, S. Sidali, Olga Giouleme +7 more
2024JHEP Reports11 citations Open access
Semantic Scholar
Paediatric hepatocellular adenomas: Lessons from a systematic review of relevant literature
I. Scheers, R. Tambucci, C. de Magnée, A. Pire +3 more
2024JHEP Reports9 citations Open access
Semantic Scholar
Survival in patients receiving reduced dose intensity of bevacizumab for unresectable hepatocellular carcinoma
D. Ball, J. Nault, Mathew Vithayathil, M. Allaire +4 more
2025npj Precision Oncology8 citations Open access
Semantic Scholar
Insights into hepatocellular adenomas in Asia: molecular subtypes, clinical characteristics, imaging features, and hepatocellular carcinoma risks
Subin Heo, I. Song, É. Reizine, M. Ronot +4 more
2025Journal of Liver Cancer8 citations Open access
Semantic Scholar
Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma.
J. Nault, C. Campani, T. Hirsch, Ethan Neumann +23 more
2026Journal of Hepatology7 citations
Semantic Scholar
Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy
Marta Fortuny, L. D. da Fonseca, M. Allaire, Rocío Sánchez +25 more
2025Liver international (Print)7 citations Open access
Semantic Scholar
Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study
Ningning Zhang, Kaipeng Liu, Yue-Xi Yu, Kai Yuan +20 more
2025Hepatology International7 citations
Semantic Scholar
Upfront multi‐bipolar radiofrequency ablation for HCC in transplant‐eligible cirrhotic patients with salvage transplantation in case of recurrence
Carina Boroș, O. Sutter, F. Cauchy, N. Ganne-Carrié +13 more
2024Liver international (Print)7 citations Open access
Semantic Scholar
Long‐term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma
Clémentine Alitti, Agnès Rode, Hervé Trillaud, P. Merle +12 more
2024Liver international (Print)7 citations Open access
Semantic Scholar
Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French Genomic Medicine Initiative.
C. Campani, P. L. Puig, F. Villeret, Y. Benmerabet +19 more
2026Journal of Hepatology5 citations Open access
Semantic Scholar
Germline mutations and somatic mosaicism in steatotic liver diseases and related liver carcinogenesis
E. Trépo, J. Zucman-Rossi, J. Nault
2026Nature reviews: Gastroenterology & hepatology5 citations Open access
Semantic Scholar
Early Hemostatic Treatment Could Improve 30‐Day Survival After Spontaneous Rupture of Hepatocellular Carcinoma
Apolline Commin, Chloé Métivier, M. Allaire, J. Lubrano +19 more
2025Liver international (Print)5 citations Open access
Semantic Scholar
LBA51 IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma
P. Galle, J. Bruix, R. Kloeckner, J. Trojan +16 more
2025Annals of Oncology5 citations
Semantic Scholar
LI-RADS for Diagnosing Hepatocellular Carcinoma in Patients with Noncirrhotic Chronic Hepatitis C.
Jih-Yun An, Rohee Park, Euichang Kim, Seong-Kyun Na +9 more
2025Radiology5 citations
Semantic Scholar
Prolonged survival in women with Hepatocellular Carcinoma: a French observational study.
Cécilia Busso, J. Nault, R. Layese, Alix Demory +5 more
2024Clinics And Research in Hepatology and Gastroenterology5 citations Open access
Semantic Scholar
Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC.
Sayma Chaibi, Edouard Larrey, J. Couty, P. Sultanik +7 more
2023Clinics And Research in Hepatology and Gastroenterology4 citations Open access
Semantic Scholar
Detection of Esophageal Varices and Prediction of Hepatic Decompensation in Unresectable Hepatocellular Carcinoma using AI: AI Detection of Varices and Decompensation.
Asier Rabasco Meneghetti, C. Campani, C. Roux, Z. Carrero +22 more
2026Journal of Hepatology3 citations Open access
Semantic Scholar
IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma.
P. Galle, J. Bruix, R. Kloeckner, J. Trojan +16 more
2026Journal of Clinical Oncology3 citations
Semantic Scholar
Atezolizumab–bevacizumab in very elderly with hepatocellular carcinoma: Age alone is not a limiting factor except in ALBI grade 3
Chloé Métivier, C. Campani, M. Allaire, Rémy Morello +25 more
2026JHEP Reports3 citations Open access
Semantic Scholar
Vessels encapsulating tumor clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab–bevacizumab
Alexandre Sayadi, C. Campani, A. Laurent-Bellue, M. Ziol +20 more
2026JHEP Reports3 citations Open access
Semantic Scholar
Targeting ATR to overcome cisplatin resistance in hepatoblastoma.
Pierre Morel-Ribeiro, Marianna Cornet, Jill Pilet, A. Asif-Laidin +25 more
2025Journal of Hepatology3 citations Open access
Semantic Scholar
Preliminary safety data of the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial assessing the triple combination atezolizumab-bevacizumab-ipilimumab in patients (pts) treated in systemic therapy for hepatocellular carcinoma (HCC).
P. Merle, Jean-Marie Peron, K. Le Malicot, M. Guarssifi +16 more
2024Journal of Clinical Oncology3 citations
Semantic Scholar
Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with early hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial).
P. Nahon, M. Ziol, Long Pan, J. Portal +27 more
2026Hepatology2 citations
Semantic Scholar
Clinical predictors of response to atezolizumab/bevacizumab in Child-Pugh B patients with hepatocellular carcinoma
Anne-Victoire Odent, C. Campani, Mohamed Bouattour, Y. Touchefeu +27 more
2026JHEP Reports2 citations Open access
Semantic Scholar
Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
E. Vo-Quang, C. Campani, M. Allaire, Mohamed Bouattour +16 more
2026European Journal of Cancer2 citations Open access
Semantic Scholar
The role of early MRI in assessing the risk of local tumor progression following irreversible electroporation for hepatocellular carcinoma treatment
Lorenzo-Carlo Pescatori, Mathilde Dessain, G. N'kontchou, Arthur Petit +9 more
2025International Journal of Hyperthermia2 citations Open access
Semantic Scholar
The "A-B-C" classification reveals outcome trajectories in patients with hepatocellular carcinoma under atezolizumab/bevacizumab.
C. Campani, Clélia Galvanin, J. Shim, Mohamed Bouattour +31 more
2025Clinical Gastroenterology and Hepatology2 citations Open access
Semantic Scholar
Utility of tumor and non-tumor biopsies during percutaneous radiofrequency ablation for hepatocellular carcinoma
L. Blaise, M. Ziol, C. Campani, N. Ganne-Carrié +13 more
2025JHEP Reports2 citations Open access
Semantic Scholar
Palliative Care Referral Practices and Impact on Survival of Patients Diagnosed With Advanced Hepatocellular Carcinoma
A. Dupuis, Alix Demory, E. Gigante, Mohamed Bouattour +8 more
2025Liver international (Print)2 citations Open access
Semantic Scholar
1471MO Adding ipilimumab (IPI) to atezolizumab (ATEZO) plus bevacizumab (BEV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in first-line systemic therapy (1L): PRODIGE 81/FFCD 2101 - TRIPLET HCC
P. Merle, J. Blanc, J. Edeline, K. Le Malicot +16 more
2025Annals of Oncology2 citations Open access
Semantic Scholar
Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study
J. Nault, Nanthara Sritharan, G. Verset, I. Borbath +18 more
2024JHEP Reports2 citations Open access
Semantic Scholar
Laparoscopic or Open Liver Resection Versus Multibipolar Radiofrequency Ablation of HCC Within Milan Criteria on Cirrhosis
C. Hobeika, F. Cauchy, Agnès Rode, E. Salamé +22 more
2026Liver international (Print)1 citations Open access
Semantic Scholar
Long-term survival and cure fraction in patients with advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data.
C. Campani, J. Shim, M. Bouattour, Y. Touchefeu +25 more
2026Clinical Cancer Research1 citations
Semantic Scholar
Comparative evaluation of regression and machine-learning models for hepatocellular carcinoma risk stratification across diverse aetiologies
P. Nahon, R. Layese, P. Natella, Lucia Parlati +10 more
2026JHEP Reports1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

P. Nahon×18
Invite
P. Nahon — researcher profile on SciRah
M. Allaire×17
Invite
M. Allaire — researcher profile on SciRah
N. Ganne-Carrié×16
Invite
N. Ganne-Carrié — researcher profile on SciRah
S. Sidali×13
Invite
S. Sidali — researcher profile on SciRah

×13

Invite

C. Campani — researcher profile on SciRah

Invite

O. Sutter — researcher profile on SciRah

Invite

L. Blaise — researcher profile on SciRah

Invite

M. Lequoy — researcher profile on SciRah

Invite

C. Campani — researcher profile on SciRah

Invite

G. Amaddeo — researcher profile on SciRah

Mohamed Bouattour×9

Invite

Mohamed Bouattour — researcher profile on SciRah

N. Ganne-Carrié×8

Invite

N. Ganne-Carrié — researcher profile on SciRah